This company listing is no longer active
La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Medlab Clinical Performance dei guadagni passati
Il passato criteri di controllo 0/6
Medlab Clinical's earnings have been declining at an average annual rate of -18.9%, while the Biotechs industry saw earnings growing at 19.6% annually. Revenues have been declining at an average rate of 19.2% per year.
Informazioni chiave
-18.9%
Tasso di crescita degli utili
-7.9%
Tasso di crescita dell'EPS
| Biotechs Crescita del settore | 9.6% |
| Tasso di crescita dei ricavi | -19.2% |
| Rendimento del capitale proprio | -108.3% |
| Margine netto | -541.7% |
| Ultimo aggiornamento sui guadagni | 30 Jun 2022 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Shareholders May Be More Conservative With Medlab Clinical Limited's (ASX:MDC) CEO Compensation For Now
Oct 06
Is Medlab Clinical (ASX:MDC) In A Good Position To Invest In Growth?
Oct 05What We Learned About Medlab Clinical's (ASX:MDC) CEO Pay
Feb 21Medlab Clinical (ASX:MDC) Share Prices Have Dropped 69% In The Last Three Years
Dec 30
Medlab Clinical Limited (ASX:MDC) Is Expected To Breakeven In The Near Future
Nov 22Ripartizione dei ricavi e delle spese
Come Medlab Clinical guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
| Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 30 Jun 22 | 2 | -8 | 12 | 2 |
| 31 Mar 22 | 1 | -9 | 9 | 1 |
| 31 Dec 21 | 4 | -12 | 11 | 1 |
| 30 Sep 21 | 4 | -12 | 11 | 2 |
| 30 Jun 21 | 1 | -10 | 11 | 2 |
| 31 Mar 21 | 1 | -10 | 10 | 2 |
| 31 Dec 20 | 1 | -11 | 9 | 2 |
| 30 Sep 20 | 2 | -12 | 9 | 2 |
| 30 Jun 20 | 3 | -13 | 10 | 2 |
| 31 Mar 20 | 4 | -12 | 10 | 2 |
| 31 Dec 19 | 4 | -12 | 11 | 2 |
| 30 Sep 19 | 5 | -10 | 10 | 1 |
| 30 Jun 19 | 5 | -8 | 10 | 1 |
| 31 Mar 19 | 5 | -7 | 8 | 1 |
| 31 Dec 18 | 5 | -6 | 7 | 0 |
| 30 Sep 18 | 4 | -5 | 7 | 0 |
| 30 Jun 18 | 4 | -5 | 6 | 0 |
| 31 Mar 18 | 4 | -4 | 6 | 0 |
| 31 Dec 17 | 5 | -4 | 6 | 0 |
| 30 Sep 17 | 5 | -4 | 5 | 0 |
| 30 Jun 17 | 4 | -4 | 5 | 0 |
| 31 Mar 17 | 4 | -4 | 5 | 0 |
| 31 Dec 16 | 4 | -4 | 4 | 0 |
| 30 Sep 16 | 3 | -4 | 4 | 0 |
| 30 Jun 16 | 3 | -3 | 4 | 0 |
Guadagni di qualità: MDC is currently unprofitable.
Margine di profitto in crescita: MDC is currently unprofitable.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: MDC is unprofitable, and losses have increased over the past 5 years at a rate of 18.9% per year.
Accelerare la crescita: Unable to compare MDC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Guadagni vs Settore: MDC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.2%).
Rendimento del capitale proprio
ROE elevato: MDC has a negative Return on Equity (-108.25%), as it is currently unprofitable.